Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

Commencing on January8, 2018, Eagle Pharmaceuticals,Inc., or the Company, will host investor meetings using, and on January10, 2018 will present, the attached discussion of the Company’s business model, products, and product candidates at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California, being held January8 — 11, 2018.

A copy of the above-referenced presentation is furnished as Exhibit99.1 to this Current Report on Form8-K. The information furnished to Item 7.01 of this current report, including Exhibit99.1, shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended. As such, this information shall not be incorporated by reference into any of the Company’s reports or other filings made with the Securities and Exchange Commission. The furnishing of the information in this current report is not intended to, and does not, constitute a determination or admission by the Company that the information in this current report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

99.1

Presentation of the Company dated January2018


EAGLE PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a18-2393_1ex99d1.htm EX-99.1 Exhibit 99.1   Eagle Pharmaceuticals January 2018   Forward Looking Statements This presentation contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995,…
To view the full exhibit click here

About Eagle Pharmaceuticals,Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.